TY - JOUR
T1 - Evolving Pico Characteristics in the Early Oncology Treatment Lifecycle
T2 - Differences From Trials to Treatment Guidelines
AU - Hogervorst, M.
AU - Vreman, R. A.
AU - Mantel-Teeuwisse, A. K.
AU - Goettsch, W. G.
AU - Kesselheim, A. S.
PY - 2023/6
Y1 - 2023/6
N2 - Under the new European health technology assessment (HTA) legislation, European countries will largely need to agree on the PICO (population, intervention, comparator, outcome) elements in HTA assessments. Additionally, cross-stakeholder alignment grows in importance due to our ever-evolving healthcare landscape, such as smaller populations and increasingly advanced products. The PICO therefore becomes more subject to variation among decision-makers. This study assessed how the PICO elements evolve over the early treatment lifecycle of oncology drugs and align between stakeholders on a global level.
AB - Under the new European health technology assessment (HTA) legislation, European countries will largely need to agree on the PICO (population, intervention, comparator, outcome) elements in HTA assessments. Additionally, cross-stakeholder alignment grows in importance due to our ever-evolving healthcare landscape, such as smaller populations and increasingly advanced products. The PICO therefore becomes more subject to variation among decision-makers. This study assessed how the PICO elements evolve over the early treatment lifecycle of oncology drugs and align between stakeholders on a global level.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=d7dz6a2i7wiom976oc9ff2iqvdhv8k5x&SrcAuth=WosAPI&KeyUT=WOS:001031473301354&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.jval.2023.03.1191
DO - 10.1016/j.jval.2023.03.1191
M3 - Meeting Abstract
SN - 1098-3015
VL - 26
SP - S218-S219
JO - Value in Health
JF - Value in Health
IS - 6
ER -